Cargando…

Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study

PURPOSE: The critical role of arterial infusion chemotherapy in the multimodal treatment of extremity bone cancer has been investigated extensively, but few studies have focused on pelvic osteosarcoma. Therefore, we attempted to evaluate the clinical significance of arterial infusion chemotherapy in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xuantao, Chen, Xia, Li, Tao, Liu, Zicheng, Guo, Xiaoning, Ouyang, Zhengxiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894794/
https://www.ncbi.nlm.nih.gov/pubmed/33623429
http://dx.doi.org/10.2147/CMAR.S294677
_version_ 1783653301228666880
author Hu, Xuantao
Chen, Xia
Li, Tao
Liu, Zicheng
Guo, Xiaoning
Ouyang, Zhengxiao
author_facet Hu, Xuantao
Chen, Xia
Li, Tao
Liu, Zicheng
Guo, Xiaoning
Ouyang, Zhengxiao
author_sort Hu, Xuantao
collection PubMed
description PURPOSE: The critical role of arterial infusion chemotherapy in the multimodal treatment of extremity bone cancer has been investigated extensively, but few studies have focused on pelvic osteosarcoma. Therefore, we attempted to evaluate the clinical significance of arterial infusion chemotherapy in the treatment of pelvic osteosarcoma. PATIENTS AND METHODS: We combined a cisplatin arterial infusion regimen with multidrug systematic chemotherapy as a neoadjuvant protocol for the treatment of pelvic osteosarcoma. The course number and dosage of cisplatin arterial infusion were adjusted to achieve a maximal tumor response evaluated by contrast-enhanced MRI per RECIST 1.1. Good responders received the same systematic combination for postoperative chemotherapy, and poor responders received second-line therapy. Twelve patients with nonmetastatic high-grade pelvic osteosarcoma were included. Survival, chemotherapy response and adverse events data were analyzed. RESULTS: The mean follow-up period was 56.1 months. Four patients died of refractory tumor progression, and 1 patient with local recurrence had no evidence of disease for 27 months after receiving secondary amputation and resection. Kaplan-Meier survival analysis demonstrated a 57.8% overall survival and 52.5% event-free survival rate at 5 years. Eight of 12 patients had a >90% tumor necrosis rate according to histopathologic examinations. The rates of local adverse events were lower than those reported for extremity osteosarcoma. CONCLUSION: Our study initially indicated that the cisplatin arterial infusion regimen was a potential therapy with good tolerance in the treatment of pelvic osteosarcoma.
format Online
Article
Text
id pubmed-7894794
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78947942021-02-22 Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study Hu, Xuantao Chen, Xia Li, Tao Liu, Zicheng Guo, Xiaoning Ouyang, Zhengxiao Cancer Manag Res Original Research PURPOSE: The critical role of arterial infusion chemotherapy in the multimodal treatment of extremity bone cancer has been investigated extensively, but few studies have focused on pelvic osteosarcoma. Therefore, we attempted to evaluate the clinical significance of arterial infusion chemotherapy in the treatment of pelvic osteosarcoma. PATIENTS AND METHODS: We combined a cisplatin arterial infusion regimen with multidrug systematic chemotherapy as a neoadjuvant protocol for the treatment of pelvic osteosarcoma. The course number and dosage of cisplatin arterial infusion were adjusted to achieve a maximal tumor response evaluated by contrast-enhanced MRI per RECIST 1.1. Good responders received the same systematic combination for postoperative chemotherapy, and poor responders received second-line therapy. Twelve patients with nonmetastatic high-grade pelvic osteosarcoma were included. Survival, chemotherapy response and adverse events data were analyzed. RESULTS: The mean follow-up period was 56.1 months. Four patients died of refractory tumor progression, and 1 patient with local recurrence had no evidence of disease for 27 months after receiving secondary amputation and resection. Kaplan-Meier survival analysis demonstrated a 57.8% overall survival and 52.5% event-free survival rate at 5 years. Eight of 12 patients had a >90% tumor necrosis rate according to histopathologic examinations. The rates of local adverse events were lower than those reported for extremity osteosarcoma. CONCLUSION: Our study initially indicated that the cisplatin arterial infusion regimen was a potential therapy with good tolerance in the treatment of pelvic osteosarcoma. Dove 2021-02-15 /pmc/articles/PMC7894794/ /pubmed/33623429 http://dx.doi.org/10.2147/CMAR.S294677 Text en © 2021 Hu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Hu, Xuantao
Chen, Xia
Li, Tao
Liu, Zicheng
Guo, Xiaoning
Ouyang, Zhengxiao
Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study
title Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study
title_full Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study
title_fullStr Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study
title_full_unstemmed Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study
title_short Effect of Cisplatin Arterial Infusion (CAI) on Primary Nonmetastatic Pelvic Osteosarcoma: A Preliminary Study
title_sort effect of cisplatin arterial infusion (cai) on primary nonmetastatic pelvic osteosarcoma: a preliminary study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894794/
https://www.ncbi.nlm.nih.gov/pubmed/33623429
http://dx.doi.org/10.2147/CMAR.S294677
work_keys_str_mv AT huxuantao effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy
AT chenxia effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy
AT litao effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy
AT liuzicheng effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy
AT guoxiaoning effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy
AT ouyangzhengxiao effectofcisplatinarterialinfusioncaionprimarynonmetastaticpelvicosteosarcomaapreliminarystudy